National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 8267 [2022-03055]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 30 / Monday, February 14, 2022 / Notices
Contact Person: Amy Williams, NCI, Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive, Building 31,
Room 10A28, Bethesda, MD 20892, (301)
496–9723, williaam@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCRA: https://
deainfo.nci.nih.gov/advisory/ncra/ncra.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 9, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–03091 Filed 2–11–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jspears on DSK121TN23PROD with NOTICES1
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; International Research
Fellowship Award Program of the
National Institute on Drug Abuse
(NIDA)
ACTION:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; High impact,
Interdisciplinary Science in NIDDK Research
Areas (RC2 Clinical Trial Optional): Celiac
Disease.
Date: March 25, 2022.
Time: 2:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Jkt 256001
[FR Doc. 2022–03055 Filed 2–11–22; 8:45 am]
National Institutes of Health,
HHS.
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
17:54 Feb 11, 2022
Dated: February 8, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
AGENCY:
National Institutes of Health
VerDate Sep<11>2014
Place: NIDDK-Democracy 2, DEM 2, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 7017, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davila-bloomm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection via application
forms, the National Institute on Drug
Abuse (NIDA), the National Institutes of
Health (NIH) will publish periodic
summaries of proposed collections to be
submitted to the Office of Management
and Budget (OMB) for review and
approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Dr. Lindsey Friend, Director,
Research Training Program Officer,
NIDA International Program, National
Institute on Drug Abuse, National
Institutes of Health, 3WFN MSC 6024,
301 North Stonestreet Avenue,
Bethesda, Maryland 20892 or call nontoll-free number (301) 402–1428 or
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
8267
Email your request, including your
address to: lindsey.friend@nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title:
International Research Fellowship
Award Program of the National Institute
on Drug Abuse (NIDA), 0925–0733,
expiration date 03/31/2022
EXTENSION, National Institute on Drug
Abuse (NIDA), National Institutes of
Health (NIH).
Need and Use of Information
Collection: These programs offer grants
and traineeships necessary for growing
the biomedical researcher workforce,
and the diversity in this workforce. The
application forms will collect
information of applicants for selecting
those that would benefit most
effectively from the programs. NIDA is
requesting approval from OMB for
application forms to be used by these
programs that will recruit pre-college
through post-doctoral underrepresented
individuals and individuals of special
populations into the research programs
of the Institute for research training and
research development, for forging
mentor/mentee relationships and
networking between newly funded
underrepresented researchers and
experienced investigators funded by
NIDA; and for a fellowship program to
train new researchers, and support
experienced researchers of other
nations, in research to advance the
biomedical and behavioral science of
drug abuse and addiction while
fostering multinational research in this
SUPPLEMENTARY INFORMATION:
E:\FR\FM\14FEN1.SGM
14FEN1
]]>Agencies
[Federal Register Volume 87, Number 30 (Monday, February 14, 2022)]
[Notices]
[Page 8267]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03055]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; High impact,
Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical
Trial Optional): Celiac Disease.
Date: March 25, 2022.
Time: 2:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: NIDDK-Democracy 2, DEM 2, 6707 Democracy Blvd., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7017, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7637, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: February 8, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-03055 Filed 2-11-22; 8:45 am]
BILLING CODE 4140-01-P
